NO944210L - Minimalisering av progestin-forbundet uregelmessig blödning - Google Patents

Minimalisering av progestin-forbundet uregelmessig blödning

Info

Publication number
NO944210L
NO944210L NO944210A NO944210A NO944210L NO 944210 L NO944210 L NO 944210L NO 944210 A NO944210 A NO 944210A NO 944210 A NO944210 A NO 944210A NO 944210 L NO944210 L NO 944210L
Authority
NO
Norway
Prior art keywords
progestin
minimization
irregular bleeding
associated irregular
bleeding
Prior art date
Application number
NO944210A
Other languages
English (en)
Other versions
NO308581B1 (no
NO944210D0 (no
Inventor
Gary D Hodgen
Original Assignee
Hampton Roads Medical College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hampton Roads Medical College filed Critical Hampton Roads Medical College
Publication of NO944210L publication Critical patent/NO944210L/no
Publication of NO944210D0 publication Critical patent/NO944210D0/no
Publication of NO308581B1 publication Critical patent/NO308581B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
NO944210A 1992-05-06 1994-11-04 Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse NO308581B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/US1992/003574 WO1993021926A1 (en) 1992-05-06 1992-05-06 Minimizing progestin associated breakthrough bleeding
PCT/US1993/004003 WO1993021927A1 (en) 1992-05-06 1993-05-03 Minimizing progestin associated breakthrough bleeding

Publications (3)

Publication Number Publication Date
NO944210L true NO944210L (no) 1994-11-04
NO944210D0 NO944210D0 (no) 1994-11-04
NO308581B1 NO308581B1 (no) 2000-10-02

Family

ID=22231028

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944210A NO308581B1 (no) 1992-05-06 1994-11-04 Anvendelse av et antiprogestin og et progestin ved fremstilling av et medikament, implantat samt prevensjonssett inneholdende disse

Country Status (17)

Country Link
EP (1) EP0646008B1 (no)
JP (1) JP3937240B2 (no)
KR (1) KR950700745A (no)
CN (1) CN1073422C (no)
AT (1) ATE187644T1 (no)
AU (2) AU1918092A (no)
CA (1) CA2131911C (no)
DE (1) DE69327319T2 (no)
DK (1) DK0646008T3 (no)
ES (1) ES2142345T3 (no)
FI (1) FI945207A (no)
GR (1) GR3032797T3 (no)
NO (1) NO308581B1 (no)
NZ (1) NZ253405A (no)
PT (1) PT646008E (no)
WO (2) WO1993021926A1 (no)
ZA (1) ZA933153B (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US5439913A (en) 1992-05-12 1995-08-08 Schering Aktiengesellschaft Contraception method using competitive progesterone antagonists and novel compounds useful therein
DE4344463A1 (de) * 1993-12-22 1995-06-29 Schering Ag Kombinationsprodukt zur Kontrazeption
EP0792152B1 (en) * 1994-11-22 2004-04-14 Balance Pharmaceuticals, Inc. Methods of contraception
US5521166A (en) * 1994-12-19 1996-05-28 Ortho Pharmaceitical Corporation Antiprogestin cyclophasic hormonal regimen
AU714959B2 (en) * 1995-02-02 2000-01-13 Schering Aktiengesellschaft Progesterone antagonists for the production of pharmaceutical agents for the treatment of dysfunctional uterine bleeding
US6506390B2 (en) 1996-06-25 2003-01-14 Akzo Nobel Progestogen-anti-progestogen regimens
TR199802705T2 (xx) * 1996-06-25 1999-03-22 Akzo Nobel N.V. Progestojen-anti-progestojen k�r�
AU747710B2 (en) 1997-11-14 2002-05-23 Akzo Nobel N.V. Progestogen-antiprogestogen regimens
US6020328A (en) * 1998-03-06 2000-02-01 Research Triangle Institute 20-keto-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US6262042B1 (en) 1998-05-29 2001-07-17 Research Triangle Institute 17β-amino and hydroxylamino-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
US5962444A (en) * 1998-05-29 1999-10-05 Research Triangle Institute 17β-nitro-11β-arylsteroids and their derivatives having agonist or antagonist hormonal properties
RU2234321C2 (ru) * 1999-04-29 2004-08-20 Акцо Нобель Н.В. Применение антипрогестагенов в комбинированной терапии
US8193252B1 (en) 1999-08-31 2012-06-05 Bayer Pharma AG Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hormone dependent gynecological disorders
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
GB0010683D0 (en) * 2000-05-03 2000-06-28 Univ Bristol Cancer therapy
DE102007023614A1 (de) 2007-05-21 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007049630A1 (de) 2007-10-11 2009-10-29 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007032800A1 (de) 2007-07-10 2009-01-15 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
DE102007058747A1 (de) 2007-12-05 2009-06-10 Bayer Schering Pharma Aktiengesellschaft Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2070909A1 (de) 2007-12-15 2009-06-17 Bayer Schering Pharma AG Nichtsteroidale Progesteronrezeptor-Modulatoren
EP2123279A1 (de) * 2008-05-14 2009-11-25 Bayer Schering Pharma Aktiengesellschaft Sequentielle Verabreichung von 20,20,21,21,21-Pentafluor-17-hydroxy-1 1beta-[4-(hydroxyacetyl) phenyl]-19-nor-17alpha-pregna-4,9-dien-3-on und einem oder mehreren Gestagenen zur Behandlung gynäkologischer Erkrankungen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA935617B (en) * 1992-08-14 1994-03-07 Akzo Nv Antiprogestogen containing contraceptives.

Also Published As

Publication number Publication date
AU4368593A (en) 1993-11-29
DE69327319T2 (de) 2000-07-13
EP0646008A4 (en) 1995-10-11
ZA933153B (en) 1993-12-06
WO1993021926A1 (en) 1993-11-11
AU667729B2 (en) 1996-04-04
FI945207A0 (fi) 1994-11-04
CA2131911C (en) 2005-12-27
CN1073422C (zh) 2001-10-24
FI945207A (fi) 1994-11-04
CA2131911A1 (en) 1993-11-11
PT646008E (pt) 2000-04-28
WO1993021927A1 (en) 1993-11-11
DE69327319D1 (de) 2000-01-20
NO308581B1 (no) 2000-10-02
JPH08509456A (ja) 1996-10-08
DK0646008T3 (da) 2000-05-15
NO944210D0 (no) 1994-11-04
KR950700745A (ko) 1995-02-20
CN1079651A (zh) 1993-12-22
ES2142345T3 (es) 2000-04-16
EP0646008B1 (en) 1999-12-15
EP0646008A1 (en) 1995-04-05
JP3937240B2 (ja) 2007-06-27
ATE187644T1 (de) 2000-01-15
GR3032797T3 (en) 2000-06-30
AU1918092A (en) 1993-11-29
NZ253405A (en) 1997-06-24

Similar Documents

Publication Publication Date Title
NO944210L (no) Minimalisering av progestin-forbundet uregelmessig blödning
FI963424A (fi) Menetelmä terapeuttisesti aktiivisten tiofeenisulfonamidien valmistamiseksi
GR3023825T3 (en) Benzopyran derivatives, processes for their preparation and their use and preparations containing the compounds
TW221056B (no)
IL94278A0 (en) 2-saccharine derivatives,their preparation and pharmaceutical compositions containing them
DZ1910A1 (fr) Nouvelles streptogramines et procédé de préparation de streptogramines par mutasynthèse.
GR3005736T3 (no)
IL89401A0 (en) Medicaments containing 1,4-dihydropyridine derivatives for the treatment of alcohol addiction
NO178782C (no) Fremgangsmåte for fremstilling av et farmasöytisk akseptabelt gelpreparat
SE8900685D0 (sv) New compounds
ITMI921429A1 (it) Composto non mutageno per il trattamento della dissenteria dei suini
MX9706825A (es) El uso farmacologico de ciertos derivados de cistina.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees